Based on cost-effectiveness estimates and a lack of comparison against afatinib, NICE will recommend against using osimertinib for first-line treatment of NSCLC.
The guidance is meant to help provide the pharma industry, researchers, and IRBs with information to facilitate studies of oncology drugs for pediatric patients.
The data showed that population screening for BRCA mutations in Ashkenazi Jewish population doesn't diminish quality of life or cause psychological distress.
The Ventana PD-L1 assay was approved as a complementary diagnostic for bladder cancer patients being considered for treatment with the immunotherapy Imfinzi.
